WVE files amended 8-K; corrected Exhibit 99.1, Research Day recap

Rhea-AI Filing Summary

Wave Life Sciences filed an 8-K/A to correct a typographical error in Exhibit 99.1 of a prior 8-K and furnished the corrected press release. The company also hosted a Research Day webcast and issued a release summarizing key updates, including positive target engagement data from the ongoing INLIGHT clinical trial evaluating WVE-007 for obesity. Certain information was furnished under Item 7.01 and incorporated by reference under Item 8.01.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

true 0001631574 0001631574 2025-10-29 2025-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

WAVE LIFE SCIENCES LTD.

(Exact name of registrant as specified in its charter)

Singapore		001-37627		98-1356880
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
7 Straits View #12-00, Marina One East Tower Singapore				018936
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: +65 6236 3388

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
$0 Par Value Ordinary Shares		WVE		The Nasdaq Global Market

Explanatory Note.

This Amendment No. 1 on Form 8-K/A (the “Amended Current Report”) amends the Current Report on Form 8-K of Wave Life Sciences Ltd. (the “Company”), originally filed with the Securities and Exchange Commission on October 29, 2025 (the “Original Filing”). Its purpose is to correct a typographical error in the first sub-bullet under “WVE-007 (GalNAc-siRNA)” – “Next steps” in the version of the press release that was attached as Exhibit 99.1 to the Original Filing. The corrected version of the press release that was issued by the Company is attached as Exhibit 99.1 to this Amended Current Report.

Item 7.01 Regulation FD Disclosure.

On October 29, 2025, Wave Life Sciences Ltd. (the “Company”) hosted a virtual analyst and investor Research Day webcast and shared a slide presentation that is available on the “Investors” section of the Company’s website at http://ir.wavelifesciences.com/.

In addition, on October 29, 2025, the Company issued a press release summarizing the key information presented during the Research Day webcast, including positive target engagement data from the Company’s ongoing INLIGHT clinical trial evaluating WVE-007 for obesity. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

The information set forth in the press release referred to in Item 7.01 above, other than the second paragraph thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by Wave Life Sciences Ltd. dated October 29, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WAVE LIFE SCIENCES LTD.
By:		/s/ Paul B. Bolno, M.D.
		Paul B. Bolno, M.D.
		President and Chief Executive Officer

Date: October 30, 2025

FAQ

What did Wave Life Sciences (WVE) change in this 8-K/A?

The company corrected a typographical error in Exhibit 99.1 and furnished a corrected press release.

What event did WVE disclose alongside the amendment?

Wave hosted a virtual Research Day webcast and shared a slide presentation on its website.

What clinical program was highlighted by WVE in the press release?

The release noted positive target engagement data from the INLIGHT trial evaluating WVE-007 for obesity.

Which items of the report apply to the WVE disclosures?

Information was furnished under Item 7.01 and incorporated by reference into Item 8.01.

What is Exhibit 99.1 in WVE’s filing?

It is the corrected press release dated October 29, 2025.

Where can investors access WVE’s Research Day materials?

The slide presentation is available on the Investors section of the company’s website.